Tofacitinib for the Treatment of Steroid-Induced Rosacea.

Purpose: Conventional treatment suffers from a dilemma of poor efficacy. The clinical use of Janus kinase (JAK) inhibitors in the treatment of steroid-induced rosacea has rarely been explored. Patients and Methods: We present a case of steroid-induced rosacea successfully treated with JAK inhibitor tofacitinib, with no adverse effects. Results: This case report of successful treatment shows a good clinical efficacy of JAK inhibitors tofacitinib in the treatment of SIR. Conclusion: JAK inhibitor tofacitinib may be a promising agent for the treatment with steroid-induced rosacea, especially for patients who have failed to conventional therapy.